FDA’s first new motion sickness drug in decades may matter more for GLP-1 side effects

The FDA’s Dec. 30 approval of Vanda Pharmaceuticals’ Nereus (tradipitant) adds a rare new option to a category that has leaned for decades on older anticholinergics and antihistamines, including the scopolamine patch and over-the-counter products such as meclizine and dimenhydrinate. In reporting on the decision, Reuters noted the approval as the first new FDA-cleared treatment… The post FDA’s first new motion sickness drug in decades may matter more for GLP-1 side effects appeared first on Drug Discovery and Development.

Continue reading →